Open discussion

Clinical Cancer Research

Volumn 13, Issue 2 II, 2007, Pages

  Atkins, ^a   George, ^a   Rini, ^a   Figlin, ^a   Flaherty, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; HEMOGLOBIN; IMATINIB; IMMUNOMODULATING AGENT; SORAFENIB; SUNITINIB; VON HIPPEL LINDAU PROTEIN; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AXITINIB; PLATELET DERIVED GROWTH FACTOR; SEMAXANIB; VASCULOTROPIN; VATALANIB;

CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; MONOTHERAPY; MULTIVARIATE ANALYSIS; NOTE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ARTHRALGIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOPENIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG INHIBITION; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE LOSS; HAND FOOT SYNDROME; HYPERTENSION; IC 50; LEUKEMIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PROTEIN EXPRESSION; PROTEINURIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; CYTOKINES; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; KIDNEY NEOPLASMS; PHENOTYPE; PLATELET-DERIVED GROWTH FACTOR; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33846862223     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2044     Document Type: Note

References (25)

1. Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med 1998;243:535-9.
2. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-82.
3. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439-43.
4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
5. Fabbro D, Manley PW. Su-6668. SUGEN. Curr Opin Investig Drugs 2001;2:1142-8.
6. Ye C, Sweeny D, Sukbuntherng J, et al. Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicol In vitro 2006;20:154-62.
7. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(32)-ylidene-methyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46:1116-9.
8. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
9. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
10. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93.
11. Manning WC, Bello CL, Deprimo SE, et al. Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2003;22:abstr 786. Ref. type: Generic.
12. Rosen L, Mulay M, Longe J, et al. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 2003;22:abtsr 765. 2006. Ref. type: Generic.
13. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
14. Motzer RJ, Rini BI, Michaelson M, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Rini BI MMRBHGWGeal, editor. Proc Am Soc Clin Oncol 2005;23:abstr 4508. 6-6-2005. Ref. type: Generic.
15. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-83.
16. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
17. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a phar-macodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23:5464-73.
18. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 2005;23:380s. Ref. type: Generic.
19. Escudier B, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005;23:4510. Ref. type: Generic.
20. George D, Michaelson D, Oh Wk, et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003;22:385. Abstract 1548. 2003. Ref. type: Generic.
21. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
22. Wickman G, Hallin M. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG013736, in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc Am Assoc Clin Cancer Res 2003;44:A3780. Ref. type: Generic.
23. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
24. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
25. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.